New York State Common Retirement Fund Sells 7,500 Shares of Regeneron Pharmaceuticals, Inc. $REGN

New York State Common Retirement Fund lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 120,569 shares of the biopharmaceutical company’s stock after selling 7,500 shares during the quarter. New York State Common Retirement Fund owned 0.11% of Regeneron Pharmaceuticals worth $67,792,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $31,000. Traub Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $38,000. Berbice Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 60 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 35 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $749.44 on Friday. The firm has a 50-day moving average price of $758.68 and a two-hundred day moving average price of $648.66. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a market capitalization of $78.77 billion, a P/E ratio of 17.95, a P/E/G ratio of 1.96 and a beta of 0.39. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the business earned $12.46 earnings per share. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on REGN. Canaccord Genuity Group increased their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Citigroup raised their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. HSBC began coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a “buy” rating and a $255.00 price target on the stock. Finally, Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 8th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $784.77.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.